|
US20100111856A1
(en)
*
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP2185188B1
(en)
|
2007-08-22 |
2014-08-06 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
|
MX2010003718A
(es)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
|
|
SI2454284T1
(en)
|
2009-07-15 |
2018-07-31 |
Aimm Therapeutics B.V. |
Compounds that specifically bind to Gram-positive bacteria
|
|
EP2507381A4
(en)
*
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
|
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
|
WO2011082187A1
(en)
*
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
|
DK2528625T3
(da)
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
BR112012030311A2
(pt)
|
2010-06-08 |
2017-01-24 |
Genentech Inc |
anticorpo
|
|
JP5889912B2
(ja)
|
2010-11-17 |
2016-03-22 |
ジェネンテック， インコーポレイテッド |
アラニニルメイタンシノール抗体コンジュゲート
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
WO2013093122A2
(en)
*
|
2011-12-23 |
2013-06-27 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
|
CA2864872C
(en)
*
|
2012-02-24 |
2022-07-05 |
Alteogen Inc. |
Modified antibody in which motif comprising cysteine residue is bound
|
|
NZ629283A
(en)
*
|
2012-03-16 |
2016-04-29 |
Covagen Ag |
Novel binding molecules with antitumoral activity
|
|
EP2638916A1
(en)
*
|
2012-03-16 |
2013-09-18 |
Covagen AG |
Novel binding molecules with antitumoral activity
|
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
|
WO2014004639A1
(en)
*
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
KR102006997B1
(ko)
*
|
2012-07-03 |
2019-08-02 |
한국생명공학연구원 |
ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
|
|
HRP20220455T1
(hr)
|
2012-08-31 |
2022-05-27 |
Sutro Biopharma, Inc. |
Modificirane aminokiseline koje sadrže azid grupu
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
AU2013328674B2
(en)
|
2012-10-12 |
2017-06-22 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10751346B2
(en)
|
2012-10-12 |
2020-08-25 |
Medimmune Limited |
Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
|
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP2906249B1
(en)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
CN105189507A
(zh)
|
2012-12-21 |
2015-12-23 |
斯皮罗根有限公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US20140187501A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Blend Therapeutics, Inc. |
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
|
|
CN103933575B
(zh)
|
2013-01-23 |
2017-09-29 |
上海新理念生物医药科技有限公司 |
一种三齿型连接子及其应用
|
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
|
BR112015019909A2
(pt)
|
2013-02-22 |
2017-08-29 |
Abbvie Stemcentrx Llc |
Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
|
|
CN110256560A
(zh)
|
2013-03-11 |
2019-09-20 |
建新公司 |
通过糖工程的位点特异性抗体-药物偶联
|
|
NZ710746A
(en)
|
2013-03-13 |
2018-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
RU2019115089A
(ru)
*
|
2013-04-16 |
2019-06-11 |
Дженентек, Инк. |
Варианты пертузумаба и их аналитическая характеристика
|
|
US9803002B2
(en)
|
2013-05-31 |
2017-10-31 |
Genentench, Inc. |
Anti-wall teichoic antibodies and conjugates
|
|
JP6506262B2
(ja)
|
2013-05-31 |
2019-04-24 |
ジェネンテック， インコーポレイテッド |
抗細胞壁タイコ酸抗体及びコンジュゲート
|
|
LT3004162T
(lt)
|
2013-05-31 |
2020-06-10 |
Genentech, Inc. |
Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
|
|
KR101899306B1
(ko)
|
2013-07-03 |
2018-10-04 |
서울대학교산학협력단 |
시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
|
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
EP3033111B1
(en)
|
2013-08-12 |
2019-03-13 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EA032231B1
(ru)
|
2013-10-11 |
2019-04-30 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
|
CA2927022C
(en)
|
2013-10-11 |
2018-08-21 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
BR112016013258A2
(pt)
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
|
JP6671292B2
(ja)
|
2013-12-16 |
2020-03-25 |
ジェネンテック， インコーポレイテッド |
ペプチド模倣化合物及びその抗体−薬物コンジュゲート
|
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
|
PE20161209A1
(es)
|
2014-02-21 |
2016-11-10 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
|
|
CN104788566A
(zh)
*
|
2014-03-11 |
2015-07-22 |
南京任诺药业有限公司 |
用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
|
|
CN104672330A
(zh)
*
|
2014-03-11 |
2015-06-03 |
南京任诺药业有限公司 |
用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
|
|
PL3129067T3
(pl)
|
2014-03-19 |
2023-05-08 |
Genzyme Corporation |
Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
|
|
US11135182B2
(en)
|
2014-04-10 |
2021-10-05 |
Af Chemicals, Llc |
Affinity medicant conjugates
|
|
US10285955B2
(en)
|
2014-04-10 |
2019-05-14 |
Af Chemicals, Llc |
Affinity medicant conjugate
|
|
WO2015157578A2
(en)
|
2014-04-10 |
2015-10-15 |
Af Chemicals, Llc |
Affinity medicant conjugates
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
RU2692563C2
(ru)
|
2014-04-25 |
2019-06-25 |
Пьер Фабр Медикамент |
Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака
|
|
EP3134438B1
(en)
|
2014-04-25 |
2020-09-30 |
Pierre Fabre Medicament |
Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
|
|
BR112016024363A2
(pt)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
|
|
US10273208B2
(en)
*
|
2014-05-23 |
2019-04-30 |
Northwestern University |
Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
WO2016040825A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
US20160074527A1
(en)
|
2014-09-17 |
2016-03-17 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
PT3204425T
(pt)
|
2014-10-09 |
2020-12-18 |
Genzyme Corp |
Conjugados anticorpo fármaco glicomanipulados
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
BR112017011478A2
(pt)
|
2014-12-03 |
2018-02-27 |
Genentech, Inc. |
composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
|
|
MX2017007169A
(es)
|
2014-12-03 |
2018-05-02 |
Genentech Inc |
Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
|
|
HK1243931A1
(zh)
|
2014-12-03 |
2018-07-27 |
F. Hoffmann-La Roche Ag |
抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
|
|
WO2016164916A1
(en)
|
2015-04-10 |
2016-10-13 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201514928D0
(en)
|
2015-08-21 |
2015-10-07 |
King S College London |
PDD compounds
|
|
WO2017050846A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Synthon Biopharmaceuticals B.V. |
Syd985 treatment of t-dm1 refractory cancer patients
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
US9669106B2
(en)
|
2015-10-26 |
2017-06-06 |
Pierre Fabre Medicament |
Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
|
|
JP6968790B2
(ja)
|
2015-10-26 |
2021-11-17 |
ピエール、ファーブル、メディカマン |
Ｉｇｆ−１ｒ発現癌の処置のための組成物
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
KR102847350B1
(ko)
|
2015-11-25 |
2025-08-19 |
주식회사 리가켐바이오사이언스 |
분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
|
|
US10689458B2
(en)
|
2015-11-30 |
2020-06-23 |
Pfizer Inc. |
Site specific HER2 antibody drug conjugates
|
|
US11135304B2
(en)
*
|
2015-12-18 |
2021-10-05 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
KR102799807B1
(ko)
|
2015-12-30 |
2025-04-24 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3423105B1
(en)
*
|
2016-03-02 |
2021-05-05 |
Eisai R&D Management Co., Ltd. |
Eribulin-based antibody-drug conjugates and methods of use
|
|
BR112018014355A2
(pt)
|
2016-03-04 |
2018-12-18 |
Genentech, Inc. |
processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
CN107789630A
(zh)
*
|
2016-10-08 |
2018-03-13 |
四川百利药业有限责任公司 |
半胱氨酸改造的抗体‑毒素偶联物及其制备方法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
SI3579883T1
(sl)
|
2017-02-08 |
2021-12-31 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin-protitelo
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
MX375569B
(es)
|
2017-02-08 |
2025-03-04 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
|
MX2019011655A
(es)
|
2017-03-29 |
2019-12-19 |
Legochem Biosciences Inc |
Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
|
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
|
PT3612537T
(pt)
|
2017-04-18 |
2022-08-29 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
|
ES2977788T3
(es)
|
2017-04-20 |
2024-08-30 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
|
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
|
DK3668874T3
(da)
|
2017-08-18 |
2022-02-14 |
Medimmune Ltd |
Pyrrolobenzodiazepin-konjugater
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP7459063B2
(ja)
|
2018-05-09 |
2024-04-01 |
レゴケム バイオサイエンシズ， インク． |
抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
|
|
MA52772A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
EP3866856A1
(en)
|
2018-10-19 |
2021-08-25 |
MedImmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CA3112977A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
EP4524569A3
(en)
|
2018-12-11 |
2025-06-18 |
AF Chemical LLC |
Methods, compositions and devices for treating cancer with illudofulvenes
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
JP7232925B2
(ja)
|
2019-02-15 |
2023-03-03 |
ウーシー バイオロジクス アイルランド リミテッド |
改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
|
|
KR102503143B1
(ko)
*
|
2019-03-06 |
2023-02-24 |
주식회사 레고켐 바이오사이언스 |
인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
KR102890251B1
(ko)
|
2019-03-15 |
2025-11-25 |
메드임뮨 리미티드 |
암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
|
|
HUE060364T2
(hu)
|
2019-03-29 |
2023-02-28 |
Medimmune Ltd |
Vegyületek és konjugátumaik
|
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
JP2022549510A
(ja)
|
2019-09-30 |
2022-11-25 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アミド結合したアミノベンズアゼピン免疫複合体、及びその使用
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
|
CA3155077A1
(en)
|
2019-10-25 |
2021-04-29 |
Romas Kudirka |
Thienoazepine immunoconjugates, and uses thereof
|
|
US11591295B2
(en)
|
2019-11-25 |
2023-02-28 |
Af Chemicals Llc |
Affinity illudofulvene conjugates
|
|
WO2021148500A1
(en)
|
2020-01-22 |
2021-07-29 |
Medimmune Limited |
Compounds and conjugates thereof
|
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
|
CN115996756A
(zh)
|
2020-05-08 |
2023-04-21 |
博尔特生物治疗药物有限公司 |
弹性蛋白酶底物肽连接子免疫缀合物及其用途
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
CN116234586A
(zh)
|
2020-08-13 |
2023-06-06 |
博尔特生物治疗药物有限公司 |
吡唑并氮呯免疫缀合物及其用途
|
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
CR20230146A
(es)
|
2020-09-11 |
2023-06-07 |
Medimmune Ltd |
Moléculas de unión a b7-h4 terapéuticas
|
|
US20240091370A1
(en)
|
2020-12-11 |
2024-03-21 |
Bolt Biotherapeutics, Inc. |
Anti-her2 immunoconjugates, and uses thereof
|
|
JP2023552791A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗ｈｅｒ２免疫複合体、及びその使用
|
|
CN116635084A
(zh)
|
2020-12-11 |
2023-08-22 |
博尔特生物治疗药物有限公司 |
抗cea免疫缀合物和其用途
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
WO2022125908A1
(en)
|
2020-12-11 |
2022-06-16 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 immunoconjugates, and uses thereof
|
|
EP4046996A1
(en)
|
2021-02-19 |
2022-08-24 |
Universität Bielefeld |
Cryptophycin compounds and conjugates thereof
|
|
WO2022197945A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
CA3212926A1
(en)
|
2021-03-26 |
2022-09-29 |
Gary Brandt |
2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
EP4649959A2
(en)
|
2021-04-14 |
2025-11-19 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CN118475372A
(zh)
|
2021-10-29 |
2024-08-09 |
博尔特生物治疗药物有限公司 |
具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
|
|
US12065496B2
(en)
|
2021-11-10 |
2024-08-20 |
Astrazeneca Ab |
Antibody molecules and conjugates
|
|
WO2023088963A1
(en)
|
2021-11-19 |
2023-05-25 |
Adc Therapeutics Sa |
Anti-il-13ralpha2 conjugates
|
|
WO2023088966A1
(en)
|
2021-11-19 |
2023-05-25 |
Adc Therapeutics Sa |
Anti-psma conjugates
|
|
CN114214341B
(zh)
*
|
2021-12-30 |
2023-12-26 |
山西大学 |
番茄SlSERAT1;1基因或其片段在植物发育过程中的应用
|
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
|
EP4230222A1
(en)
|
2022-02-17 |
2023-08-23 |
Oxsonics Limited |
Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
|
|
US20250170258A1
(en)
|
2022-02-28 |
2025-05-29 |
Adc Therapeutics Sa |
Dosage regimen
|
|
KR20240159839A
(ko)
|
2022-03-09 |
2024-11-06 |
아스트라제네카 아베 |
FRα에 대한 결합 분자
|
|
IL314452A
(en)
|
2022-03-11 |
2024-09-01 |
Astrazeneca Ab |
Scoring method for anti-frα antibody-drug treatment
|
|
CN118829451A
(zh)
*
|
2022-04-29 |
2024-10-22 |
四川科伦博泰生物医药股份有限公司 |
一类抗体药物偶联物、其药物组合物及应用
|
|
EP4543920A1
(en)
|
2022-06-27 |
2025-04-30 |
Astrazeneca AB |
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
JP2025530213A
(ja)
|
2022-09-09 |
2025-09-11 |
ミリックス ファーマ リミテッド |
Ｎｍｔ阻害剤を含む抗体薬物コンジュゲート及びその使用
|
|
US20240165257A1
(en)
|
2022-11-01 |
2024-05-23 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
|
EP4633738A1
(en)
|
2022-12-14 |
2025-10-22 |
Pheon Therapeutics Ltd |
Cytotoxic compounds
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
EP4637833A2
(en)
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
EP4410314A1
(en)
|
2023-02-02 |
2024-08-07 |
ADC Therapeutics SA |
Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
|
|
WO2024173387A1
(en)
|
2023-02-14 |
2024-08-22 |
Bolt Biotherapeutics, Inc. |
Aza-benzazepine immunoconjugates, and uses thereof
|
|
TW202448517A
(zh)
|
2023-02-16 |
2024-12-16 |
瑞典商阿斯特捷利康公司 |
用治療性結合分子治療癌症的組合療法
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
CN120936385A
(zh)
|
2023-03-13 |
2025-11-11 |
海德堡医药研究有限责任公司 |
用于在癌症治疗中使用的皮下施用的抗体-药物缀合物
|
|
WO2024223899A1
(en)
|
2023-04-28 |
2024-10-31 |
Medimmune Limited |
B7-h4 therapeutic binding molecules for the treatment of cancer
|
|
WO2025083067A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-claudin-6 conjugates
|
|
WO2025083064A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-asct2 conjugates
|
|
WO2025083061A1
(en)
|
2023-10-17 |
2025-04-24 |
Adc Therapeutics Sa |
Anti-napi2b conjugates
|
|
EP4548936A1
(en)
|
2023-10-30 |
2025-05-07 |
BioNTech SE |
Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
|
|
WO2025109097A2
(en)
|
2023-11-24 |
2025-05-30 |
Heidelberg Pharma Research Gmbh |
Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
|
|
EP4566631A1
(en)
|
2023-12-06 |
2025-06-11 |
Heidelberg Pharma Research GmbH |
New antibody drug conjugate as well as methods of production and uses thereof
|
|
AU2024394903A1
(en)
|
2023-12-06 |
2026-04-02 |
Adc Therapeutics Sa |
Anti-psma antibody drug conjugates comprising exatecan
|
|
WO2025134068A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Antibody drug conjugates targeting proteinopathies, and uses thereof
|
|
GB202403391D0
(en)
|
2024-03-08 |
2024-04-24 |
Myricx Pharma Ltd |
Novel compounds and their use in therapy
|
|
GB202405758D0
(en)
|
2024-04-24 |
2024-06-05 |
King S College London |
Compounds
|
|
GB202407700D0
(en)
|
2024-05-30 |
2024-07-17 |
Francis Crick Institute Ltd |
F-actin binding agents
|
|
WO2026006689A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Bcl-xl degrader antibody conjugates and uses thereof
|
|
WO2026006688A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Degrader antibody conjugates and uses thereof
|
|
WO2026020031A2
(en)
|
2024-07-18 |
2026-01-22 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|
|
EP4706676A1
(en)
*
|
2024-09-10 |
2026-03-11 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cysteine-engineered antigen-binding domains
|
|
EP4706675A1
(en)
*
|
2024-09-10 |
2026-03-11 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Cysteine-engineered chimeric antigen receptor
|
|
WO2026057740A1
(en)
|
2024-09-12 |
2026-03-19 |
Astrazeneca Ab |
Treatment of cancer with therapeutic binding molecules
|
|
WO2026078620A1
(en)
|
2024-10-11 |
2026-04-16 |
Medimmune Llc |
Cd22 antibody and drug conjugates and uses thereof
|